Artera Secures FDA Clearance for ArteraAI Breast

According to a Business Wire release, Artera received U.S. Food and Drug Administration (FDA) clearance for ArteraAI Breast for use in patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer. Business Wire and MPO report that Artera describes ArteraAI Breast as the "first and only FDA-cleared digital pathology-based risk stratification tool for breast cancer." The tool produces an AI-derived risk score intended to estimate the likelihood of distant metastasis and to stratify patients into predefined low- and high-risk groups, per company reporting. MPO and MedicalDeviceNetwork note that the algorithm uses digitized histopathology images together with patient clinical variables. A company quote in Business Wire records Andre Esteva, CEO and co-founder of Artera, saying, "FDA clearance for ArteraAI Breast represents a significant expansion of our FDA-cleared AI platform in oncology." MPO additionally reports a comment from Eric Winer, MD, who called the clearance "an important advance on the road to personalizing treatments for patients with early-stage breast cancer."

Editorial analysis - technical context: Public reporting indicates ArteraAI Breast integrates digital whole-slide images and standard clinical features to compute a prognostic score for distant metastasis risk in HR+/HER2- disease. The product's output is a binary stratification around a predefined cutoff, as described in the coverage, which is a common design for pathology-derived clinical decision support that aims to align with existing treatment frameworks. Multiple outlets cite data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) as the clinical dataset used to evaluate performance and potential chemotherapy benefit signals in subgroups.

FDA clearance for an AI tool that is explicitly pathology-image based represents a regulatory milestone for digital pathology applications, reported across Business Wire, MPO, and MedicalDeviceNetwork. Coverage also highlights that Artera previously obtained regulatory milestones for its prostate assay, and reporting states the company has a CE mark for its breast cancer assay in Europe. For practitioners, the item reinforces a broader pattern where regulators are increasingly evaluating image-first prognostic tools alongside clinical variables, and where published conference data (SABCS) are used to support clinical utility claims.

Observers will likely monitor peer-reviewed publication of the SABCS dataset analyses, real-world integration into pathology workflows, and independent validation studies cited by payers or guideline committees. Reporting does not provide timelines for clinical rollout or reimbursement; those remain subject to future announcements.